FDA supplemental approval: Pomalidomide (REMS)

AI Summary

This is a regulatory action by the FDA, not a clinical trial or evidence summary. The record documents a supplemental approval dated 27 April 2026 for a REMS (Risk Evaluation and Mitigation Strategy) submission by Breckenridge for pomalidomide capsules across four dose strengths (1, 2, 3, and 4 mg). The record does not contain clinical trial results, efficacy data, or safety evidence.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide; this is a regulatory action, not a clinical evidence assessment.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record documents a regulatory approval of risk management procedures for pomalidomide. It does not establish clinical efficacy, comparative benefit, or safety outcomes. Clinicians should refer to the pomalidomide prescribing information and REMS program requirements for guidance on appropriate use.

Caveats

• This record contains no clinical trial results, efficacy data, or comparative safety evidence.
• The REMS approval itself does not indicate clinical superiority or new indications.
• No information is provided on the specific REMS requirements or restrictions imposed.
• Source does not report sample size, study population, outcomes, or p-values.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.